Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseases

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseases

November 23, 2022

Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).

The method of use patent is on top of granted US Patent No. 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. The composition of matter protection afforded by Patent No. 11285155 is irrespective of therapeutic indication.

Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19.

“This USPTO allowance, together with the prior intellectual property secured by Kinarus in the US, EP, Australia, Eurasia, China, ARIPO and other countries, provides an even more secure IP protection for KIN001 in wet AMD and other retinal diseases," Dr. Alexander Bausch, Kinarus CEO, said in a company news release. "The positioning of KIN001 as an oral therapy in the ophthalmology space is unique. Our ambition is that KIN001 will be the first oral therapy used in combination with anti-VEGF therapies to stop progression of wet AMD and other retinal diseases in our aging population.”

KIN001 is being developed as a complementary oral therapy to existing anti-VEGF medications with the aim of extending the treatment interval between ocular injections. For a one-year phase 2 clinical research in Germany and Switzerland, Kinarus has acquired regulatory permission.

Pamapimod and pioglitazone are the two active pharmaceutical ingredients (APIs) that make up KIN001. Pamapimod is a small molecule inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway that is now in the clinical stage.

In preclinical models of wet AMD, IPF, and other fibrotic and inflammatory diseases, Kinarus has discovered that pairing pamapimod with pioglitazone, a medication that is safe and well-tolerated and is marketed for the treatment of type 2 diabetes, results in synergistic efficacy and prolonged duration of action.